DNALite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed on bringing the next-generation of drugs to organs protected by mucus barriers. Currently for diseases, such as colorectal cancer and Crohn's disease, complete or partial removal of the colon and/or rectum is the only treatment  Our aim is to prevent not manage the progression of these diseases. We are doing this by harnessing our proprietary technology to carry DNA to cells that drive these diseases.